Vision Beyond Borders: Asia-Pacific Neovascular AMD Advisory Board Meeting

Pre-meeting survey

We are looking forward to your participation in the upcoming “Vision Beyond Borders: Asia-Pacific Neovascular AMD Advisory Board Meeting”, scheduled for Saturday, 17 August 2024. The objectives of the meeting are to:

  1. Review the clinical and disease burden of nAMD and identify current obstacles to optimal management with the current standard-of-care therapies.
  2. Discuss the treatment-related factors on the relevance of disease pathway targeting and therapy mechanism of action in overcoming potential limitations of current standard-of-care approaches.
  3. Evaluate the clinical data of faricimab and come to an agreement on the appropriate positioning and use of the bispecific anti-VEGF and ANG-2 targeting agent.

To gain preliminary insights and ensure the discussion of the statements is as informed as possible, please take a moment to share your opinion and expertise by completing the following brief survey. Survey results will be presented and discussed during the meeting, and your responses will help facilitate the discussion and be significant across our diverse group of expert attendees.

Section 1 – Clinical and treatment burden
Please rate the level of agreement for each of the following statements. Please feel free to add any references that you think are relevant to the statement in the “Reference suggestion(s):” space.
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Section 2 – Treatment-related factors
Please rate the level of agreement for each of the following statements. Please feel free to add any references that you think are relevant to the statement in the “Reference suggestion(s):” space.
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Section 3 – Clinical outcomes
Please rate the level of agreement for each of the following statements. Please feel free to add any references that you think are relevant to the statement in the “Reference suggestion(s):” space.
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Strongly agreeAgreeDisagreeStrongly disagree
Strongly agree
Agree
Disagree
Strongly disagree
Thank you for your collaboration and contribution to advancing the understanding of neovascular AMD!
M-TW-00005445